Rational targeting of protein translation of cancer treatments

癌症治疗的蛋白质翻译的合理靶向

基本信息

批准号：
9089875
负责人：
France Carrier
金额：
$ 31.85万
依托单位：
UNIVERSITY OF MARYLAND BALTIMORE
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-07-01 至 2018-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9089875
关键词：
3&apos Untranslated Regions 5&apos Untranslated Regions Affect Antineoplastic Agents Apoptosis Binding Biochemical Biological Assay Cell Proliferation Cell physiology Cells Cellular Stress Characteristics Colon Carcinoma Computer Assisted DNA Repair Data Docking Dose Down-Regulation Drug Design Drug Targeting Eukaryotic Initiation Factor-4G FRAP1 gene Feedback Fibroblasts Goals Growth Health Hematologic Neoplasms Heterogeneous-Nuclear Ribonucleoproteins Histocytochemistry Human Lead Malignant - descriptor Malignant Neoplasms Malignant neoplasm of prostate Mantle Cell Lymphoma Metastatic Melanoma Molecular Molecular and Cellular Biology Mus NMR Spectroscopy Normal Cell Normal tissue morphology Nuclear Magnetic Resonance Pathway interactions Pharmaceutical Preparations Phosphorylation Proliferating Protein Translation Pathway Proteins RNA RNA Binding RNA-Binding Proteins RNA-Protein Interaction Radiation Regulatory Pathway Renal Cell Carcinoma Research Ribonucleoproteins Role Solid Solid Neoplasm Specificity Stream Stress Structure Technology Testing Toxic effect Transcript Translations Tuberous sclerosis protein complex Untranslated Regions Western Blotting Work Xenograft Model Xenograft procedure anticancer treatment base cancer cell cancer therapy clinically relevant design drug discovery human tissue inhibitor/antagonist innovation malignant breast neoplasm melanocyte melanoma novel prevent response small molecule stem structural biology targeted cancer therapy three dimensional structure tumor tumor growth tumor progression

项目摘要

DESCRIPTION (provided by applicant): Targeting protein translation for cancer therapy is an attractive strategy to limit cancer cells proliferation by depriving them of essential nutriments. However, the currently available drugs target components of the protein translational machinery that are also essential for normal cell functions. Here, we propose to develop a more rational approach by targeting a regulator of protein translation in cancer cells. Our preliminary data indicate that the stress-activated RNA binding protein hnRNP A18 confers growth advantage to cancer cells by regulating the expression of key proteins that prevent apoptosis and/or increase DNA repair. hnRNP A18 increases protein translation by binding to a specific RNA signature motif in the 3'UTRs of its targeted transcripts and interacting with the general translational machinery. Therefore, targeting hnRNP A18 could prevent protein translation in cancer cells, where hnRNP A18 is over expressed, and would only affect the translation of transcripts harboring hnRNP A18 signature motif. Our working hypothesis is that rational targeting of hnRNP A18 will inhibit the translation of specific RNA transcripts devoted to confer growth advantages to cancer cells. To test this hypothesis three specific Aims have been designed. Aim 1: Determine the role of hnRNP A18 in cancer cells sensitivity to anticancer treatments. Levels of hnRNP A18 will be manipulated and the cellular sensitivity to clinically relevant doses of anticancer drugs or radiation will be analyzed by clonogenic survival assays, apoptosis and DNA repair (γH2AX). Aim 2: Characterize the biochemical and functional binding activity of hnRNP A18 to its targeted transcripts and evaluate the effect of hnRNP A18 on cancer progression. This will be performed by systematically analyzing binding to the different stems and bulges of the hnRNP A18 RNA motif and evaluating the effect of hnRNP A18 phosphorylation on the binding to these different RNA structures. Aim 3: Determine the three-dimensional structure of hnRNP A18 and identify the hnRNP A18-RNA binding interface. The structures of unphosphorylated and phosphorylated hnRNP A18 in the absence (apo) and presence of 3'UTR RNA (signature motif) will be solved in solution by Nuclear Magnetic Resonance (NMR) spectroscopy. Our long term goal is to develop drugs that could target hnRNP A18 to control and possibly stop cancer progression. This could be accomplished by solving hnRNP A18 three dimensional structure and use computer-aided drug design (CADD) technology to identify small molecules that could target hnRNP A18.

描述（由适用提供）：针对癌症治疗的蛋白质翻译是一种有吸引力的策略，可以通过剥夺癌细胞的增殖来限制癌细胞的增殖。但是，当前可用的药物靶向蛋白质翻译机制的成分，对于正常细胞功能也是必不可少的。在这里，我们建议通过针对癌细胞中蛋白质翻译的调节剂来开发更合理的方法。我们的初步数据表明，应力激活的RNA结合蛋白HNRNP A18通过反思键蛋白的表达来防止细胞凋亡和/或增加DNA修复，从而赋予了癌细胞的生长优势。 HNRNP A18通过在其靶向转录本的3'UTR中与特定的RNA信号基序结合并与一般翻译机械相互作用，从而增加了蛋白质的翻译。因此，靶向HNRNP A18可以防止HNRNP A18过度表达的癌细胞中的蛋白质翻译，并且只会影响带有HNRNP A18签名基序的转录本的翻译。我们的工作假设是，HNRNP A18的合理靶向将抑制专用于癌细胞会议优势的特定RNA转录本的翻译。为了检验该假设，已经设计了三个特定目标。 AIM 1：确定HNRNP A18在癌细胞对抗癌治疗敏感性中的作用。将操纵HNRNP A18的水平，并通过粘液生存测定，凋亡和DNA修复（γH2AX）来分析对临床相关剂量的抗癌药物或辐射的细胞敏感性。 AIM 2：表征HNRNP A18与其靶向转录本的生化和功能结合活性，并评估HNRNP A18对癌症进展的影响。这将通过系统地分析与HNRNP A18 RNA基序的不同茎和灯泡进行系统分析，并评估HNRNP A18磷酸化对与这些不同RNA结构的结合的影响。 AIM 3：确定HNRNP A18的三维结构，并识别HNRNP A18-RNA结合界面。在不存在（APO）的情况下，未磷酸化和磷酸化的HNRNP A18的结构将通过核磁共振（NMR）光谱在溶液中解决。我们的长期目标是开发可以针对HNRNP A18的药物来控制和阻止癌症的进展。这可以通过求解HNRNP A18三维结构并使用计算机辅助药物设计（CADD）技术来实现这一点，以识别可以针对HNRNP A18的小分子。